GorelikLLernerMBixlerS. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol2010; 68: 295–303.
2.
OlssonTHillertJAlfredssonL. Anti-JCV antibody prevalence in a Swedish cohort of MS patients and non-MS controls, Poster Nr. 983. In European Conference on Treatment and Research on MS (ECTRIMS), 13–16 October 2010, available at: http://www.posters2view.com/ECTRIMS2010/view.php?nu=2983.
3.
JCV Antibody Program (Stratifiy-2), ClinicalTrials.gov identifier: NCT01070836.
4.
WarnkeCAdamsOHartungHP. [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab : Recommendations for JC virus serology.]. Nervenarzt2011; 82: 1314–1319.
